Extraosseous primary and recurrent giant cell tumors: Transforming growth factor-β1 and -β2 expression may explain metaplastic bone formation

Lisa A. Teot, Regis J. O'Keefe, Randy N. Rosier, John X. O'Connell, Edward Fox, David G. Hicks

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Giant cell tumor (GCT) of bone is a locally aggressive neoplasm with a high incidence of recurrence, usually at the site of previous osseous involvement. Primary and recurrent intraosseous lesions typically are lytic and do not show evidence of tumor-associated osteogenesis. Rarely, GCT recurs or is primary within soft tissue, and not infrequently, these extraosseous lesions show metaplastic bone formation that is visible radiographically. The authors report two recurrent and one primary case of extraosseous GCT, all of which exhibited significant deposits of metaplastic bone localized to the periphery of the lesions. In situ hybridization showed messenger RNA (mRNA) for transforming growth factor β1 (TGF-b1) and transforming growth factor β2 (TGF-β2) in neoplastic stromal cells and osteoclast-like giant cells within the recurrent and primary extsaosseous tumors as well as in active osteoblasts on the surfaces of recently formed spicules of metaplastic bone. In situ hybridization also revealed mRNA for TGF-b1 and TGF-β2 in primary intraosseous tumors from these cases and from four cases in which neither extraosseous recurrence nor osseous metaplasia was identified. In the microenvironment of the extraosseous soft tissue, production of these osteoinductive growth factors by GCT may have a paracrine effect on mesenchymal progenitor cells, thereby stimulating the osteoblastic differentiation and metaplastic bone formation associated with these lesions.

Original languageEnglish (US)
Pages (from-to)625-632
Number of pages8
JournalHuman Pathology
Volume27
Issue number7
DOIs
StatePublished - Jan 1 1996

Fingerprint

Giant Cell Tumors
Transforming Growth Factors
Osteogenesis
In Situ Hybridization
Neoplasms
Giant Cell Tumor of Bone
Bone and Bones
Recurrence
Messenger RNA
Metaplasia
Osteoclasts
Giant Cells
Stromal Cells
Osteoblasts
Mesenchymal Stromal Cells
Intercellular Signaling Peptides and Proteins
Incidence

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

Teot, Lisa A. ; O'Keefe, Regis J. ; Rosier, Randy N. ; O'Connell, John X. ; Fox, Edward ; Hicks, David G. / Extraosseous primary and recurrent giant cell tumors : Transforming growth factor-β1 and -β2 expression may explain metaplastic bone formation. In: Human Pathology. 1996 ; Vol. 27, No. 7. pp. 625-632.
@article{f34e672a80014ec185dd6541b9fa3afe,
title = "Extraosseous primary and recurrent giant cell tumors: Transforming growth factor-β1 and -β2 expression may explain metaplastic bone formation",
abstract = "Giant cell tumor (GCT) of bone is a locally aggressive neoplasm with a high incidence of recurrence, usually at the site of previous osseous involvement. Primary and recurrent intraosseous lesions typically are lytic and do not show evidence of tumor-associated osteogenesis. Rarely, GCT recurs or is primary within soft tissue, and not infrequently, these extraosseous lesions show metaplastic bone formation that is visible radiographically. The authors report two recurrent and one primary case of extraosseous GCT, all of which exhibited significant deposits of metaplastic bone localized to the periphery of the lesions. In situ hybridization showed messenger RNA (mRNA) for transforming growth factor β1 (TGF-b1) and transforming growth factor β2 (TGF-β2) in neoplastic stromal cells and osteoclast-like giant cells within the recurrent and primary extsaosseous tumors as well as in active osteoblasts on the surfaces of recently formed spicules of metaplastic bone. In situ hybridization also revealed mRNA for TGF-b1 and TGF-β2 in primary intraosseous tumors from these cases and from four cases in which neither extraosseous recurrence nor osseous metaplasia was identified. In the microenvironment of the extraosseous soft tissue, production of these osteoinductive growth factors by GCT may have a paracrine effect on mesenchymal progenitor cells, thereby stimulating the osteoblastic differentiation and metaplastic bone formation associated with these lesions.",
author = "Teot, {Lisa A.} and O'Keefe, {Regis J.} and Rosier, {Randy N.} and O'Connell, {John X.} and Edward Fox and Hicks, {David G.}",
year = "1996",
month = "1",
day = "1",
doi = "10.1016/S0046-8177(96)90389-5",
language = "English (US)",
volume = "27",
pages = "625--632",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "7",

}

Extraosseous primary and recurrent giant cell tumors : Transforming growth factor-β1 and -β2 expression may explain metaplastic bone formation. / Teot, Lisa A.; O'Keefe, Regis J.; Rosier, Randy N.; O'Connell, John X.; Fox, Edward; Hicks, David G.

In: Human Pathology, Vol. 27, No. 7, 01.01.1996, p. 625-632.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Extraosseous primary and recurrent giant cell tumors

T2 - Transforming growth factor-β1 and -β2 expression may explain metaplastic bone formation

AU - Teot, Lisa A.

AU - O'Keefe, Regis J.

AU - Rosier, Randy N.

AU - O'Connell, John X.

AU - Fox, Edward

AU - Hicks, David G.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Giant cell tumor (GCT) of bone is a locally aggressive neoplasm with a high incidence of recurrence, usually at the site of previous osseous involvement. Primary and recurrent intraosseous lesions typically are lytic and do not show evidence of tumor-associated osteogenesis. Rarely, GCT recurs or is primary within soft tissue, and not infrequently, these extraosseous lesions show metaplastic bone formation that is visible radiographically. The authors report two recurrent and one primary case of extraosseous GCT, all of which exhibited significant deposits of metaplastic bone localized to the periphery of the lesions. In situ hybridization showed messenger RNA (mRNA) for transforming growth factor β1 (TGF-b1) and transforming growth factor β2 (TGF-β2) in neoplastic stromal cells and osteoclast-like giant cells within the recurrent and primary extsaosseous tumors as well as in active osteoblasts on the surfaces of recently formed spicules of metaplastic bone. In situ hybridization also revealed mRNA for TGF-b1 and TGF-β2 in primary intraosseous tumors from these cases and from four cases in which neither extraosseous recurrence nor osseous metaplasia was identified. In the microenvironment of the extraosseous soft tissue, production of these osteoinductive growth factors by GCT may have a paracrine effect on mesenchymal progenitor cells, thereby stimulating the osteoblastic differentiation and metaplastic bone formation associated with these lesions.

AB - Giant cell tumor (GCT) of bone is a locally aggressive neoplasm with a high incidence of recurrence, usually at the site of previous osseous involvement. Primary and recurrent intraosseous lesions typically are lytic and do not show evidence of tumor-associated osteogenesis. Rarely, GCT recurs or is primary within soft tissue, and not infrequently, these extraosseous lesions show metaplastic bone formation that is visible radiographically. The authors report two recurrent and one primary case of extraosseous GCT, all of which exhibited significant deposits of metaplastic bone localized to the periphery of the lesions. In situ hybridization showed messenger RNA (mRNA) for transforming growth factor β1 (TGF-b1) and transforming growth factor β2 (TGF-β2) in neoplastic stromal cells and osteoclast-like giant cells within the recurrent and primary extsaosseous tumors as well as in active osteoblasts on the surfaces of recently formed spicules of metaplastic bone. In situ hybridization also revealed mRNA for TGF-b1 and TGF-β2 in primary intraosseous tumors from these cases and from four cases in which neither extraosseous recurrence nor osseous metaplasia was identified. In the microenvironment of the extraosseous soft tissue, production of these osteoinductive growth factors by GCT may have a paracrine effect on mesenchymal progenitor cells, thereby stimulating the osteoblastic differentiation and metaplastic bone formation associated with these lesions.

UR - http://www.scopus.com/inward/record.url?scp=0029984166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029984166&partnerID=8YFLogxK

U2 - 10.1016/S0046-8177(96)90389-5

DO - 10.1016/S0046-8177(96)90389-5

M3 - Article

C2 - 8698303

AN - SCOPUS:0029984166

VL - 27

SP - 625

EP - 632

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 7

ER -